Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CTSE | P14091 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5282653 | 0.97 | REN (0.43) | RENCTSDCTSECYP3A4KCNH2 | |
| Formic Acid SCHEMBL5676917 | 0.92 | REN (0.41) | RENCTSDCTSECYP3A4 | |
| Formic Acid SCHEMBL5892343 | 0.92 | REN (0.41) | RENCTSDCTSECYP3A4KCNH2 | |
| SCHEMBL5277427 | 0.89 | REN (0.43) | RENCTSDCTSECYP3A4KCNH2 | |
| SCHEMBL5276126 | 0.89 | REN (0.43) | RENCTSDCTSECYP3A4 | |
| Formic Acid SCHEMBL5276662 | 0.87 | REN (0.47) | RENCTSDCTSECYP3A4 | |
| Formic Acid SCHEMBL5680042 | 0.87 | REN (0.45) | RENCTSDCTSECYP3A4KCNH2 | |
| SCHEMBL5274837 | 0.86 | REN (0.41) | RENCTSDCTSECYP3A4 | |
| Formic Acid SCHEMBL5675451 | 0.86 | REN (0.46) | RENCTSDCTSECYP3A4 | |
| SCHEMBL5277956 | 0.84 | REN (0.46) | RENCTSDCTSECYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620403-B1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-10-19 | — | — | US | disclosed |
| EP-1620403-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096769-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | REN, ACE, ACE2 | REN 1/4885CTSD 221/4885CTSE 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.